Study in Parkinson’s disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial

BACKGROUND: To date, no medication has slowed the progression of Parkinson’s disease (PD). Preclinical, epidemiological, and experimental data on humans all support many benefits of endurance exercise among persons with PD. The key question is whether there is a definitive additional benefit of exer...

Descripción completa

Detalles Bibliográficos
Autores principales: Patterson, Charity G., Joslin, Elizabeth, Gil, Alexandra B., Spigle, Wendy, Nemet, Todd, Chahine, Lana, Christiansen, Cory L., Melanson, Ed, Kohrt, Wendy M., Mancini, Martina, Josbeno, Deborah, Balfany, Katherine, Griffith, Garett, Dunlap, Mac Kenzie, Lamotte, Guillaume, Suttman, Erin, Larson, Danielle, Branson, Chantale, McKee, Kathleen E., Goelz, Li, Poon, Cynthia, Tilley, Barbara, Kang, Un Jung, Tansey, Malú Gámez, Luthra, Nijee, Tanner, Caroline M., Haus, Jacob M., Fantuzzi, Giamila, McFarland, Nikolaus R., Gonzalez-Latapi, Paulina, Foroud, Tatiana, Motl, Robert, Schwarzschild, Michael A., Simuni, Tanya, Marek, Kenneth, Naito, Anna, Lungu, Codrin, Corcos, Daniel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535216/
https://www.ncbi.nlm.nih.gov/pubmed/36203214
http://dx.doi.org/10.1186/s13063-022-06703-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535216/
https://www.ncbi.nlm.nih.gov/pubmed/36203214
http://dx.doi.org/10.1186/s13063-022-06703-0

Ejemplares similares